A study to minimise the risks of emergence of drug-resistant bacteria in patients with Intensive Care Unit pulmonary infection by determining the optimal approach to administer existing antimicrobial treatments

Not Applicable

• Conditions: Pulmonary infection; Infections and Infestations

• Registration Number: ISRCTN47673027
• Lead Sponsor: orth Bristol NHS Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-26
• Last Update Posted: 10 October 2022
• Study Completion: 2024-03-31

Recruitment & Eligibility

• Status: Stopped
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Intubated patients with clinician suspected Gram-negative pulmonary infection requiring antibacterial therapy
2. Adults aged 18 years upwards
3. Patient admitted to ICU for at least 5 days
4. Patient ventilated for at least 48 hours

Inclusion criteria for analysis:
Infection with a piperacillin-tazobactam and gentamicin susceptible Gram-negative organism.

Exclusion Criteria

1. Patients for whom informed consent cannot be obtained
2. Allergies or intolerance to piperacillin-tazobactam or gentamicin
3. Neutropaenic sepsis
4. Past medical history of cystic fibrosis
5. Other underlying infections pulmonary process unlikely to respond to piperacillin/tazobactam with or without gentamicin (i.e. tuberculosis, fungal pneumonia)
6. Subject unlikely to survive longer than 24 hours
7. Prisoners
8. Pregnant women
9. Non-NHS patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified